Effect and safety of rosuvastatin in acute ischemic stroke

EUREKA Investigators

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.

Original languageEnglish
Pages (from-to)87-95
Number of pages9
JournalJournal of Stroke
Volume18
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke
Safety
Placebos
Recurrence
Cerebral Hemorrhage
Subarachnoid Hemorrhage
Random Allocation
Rosuvastatin Calcium
Infarction
Magnetic Resonance Imaging
Confidence Intervals
Growth

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

EUREKA Investigators. / Effect and safety of rosuvastatin in acute ischemic stroke. In: Journal of Stroke. 2016 ; Vol. 18, No. 1. pp. 87-95.
@article{7fa0826db4ad4698abe0cdb2cbd03c4e,
title = "Effect and safety of rosuvastatin in acute ischemic stroke",
abstract = "Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-na{\"i}ve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7{\%} vs. placebo: 36/152, 23.6{\%}) (relative risk 0.83, 95{\%} confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4{\%}) than the placebo group (22/152, 14.5{\%}, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6{\%} vs. 7/159, 4.4{\%}, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.",
author = "{EUREKA Investigators} and Heo, {Ji Hoe} and Dongbeom Song and Nam, {Hyo Suk} and Kim, {Eung Yeop} and Kim, {Young Dae} and Lee, {Kyung Yul} and Lee, {Ki Jeong} and Joonsang Yoo and Kim, {Youn Nam} and Lee, {Byung Chul} and Yoon, {Byung Woo} and Kim, {Jong S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.5853/jos.2015.01578",
language = "English",
volume = "18",
pages = "87--95",
journal = "Journal of Stroke",
issn = "2287-6391",
publisher = "Korean Stroke Society",
number = "1",

}

Effect and safety of rosuvastatin in acute ischemic stroke. / EUREKA Investigators.

In: Journal of Stroke, Vol. 18, No. 1, 01.01.2016, p. 87-95.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect and safety of rosuvastatin in acute ischemic stroke

AU - EUREKA Investigators

AU - Heo, Ji Hoe

AU - Song, Dongbeom

AU - Nam, Hyo Suk

AU - Kim, Eung Yeop

AU - Kim, Young Dae

AU - Lee, Kyung Yul

AU - Lee, Ki Jeong

AU - Yoo, Joonsang

AU - Kim, Youn Nam

AU - Lee, Byung Chul

AU - Yoon, Byung Woo

AU - Kim, Jong S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.

AB - Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.

UR - http://www.scopus.com/inward/record.url?scp=84969425019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969425019&partnerID=8YFLogxK

U2 - 10.5853/jos.2015.01578

DO - 10.5853/jos.2015.01578

M3 - Article

AN - SCOPUS:84969425019

VL - 18

SP - 87

EP - 95

JO - Journal of Stroke

JF - Journal of Stroke

SN - 2287-6391

IS - 1

ER -